Key result
The review discusses the development of modern hydropericardium syndrome vaccines, highlighting the need for cell culture-adapted and attenuated vaccines over traditional liver organ inactivated vaccines.
Continuous cell lines offer a promising, safer, and more economical solution for producing cell culture-adapted and attenuated vaccines against hydropericardium syndrome in chickens.
Answers are grounded in this paper and cite their sources.
Cell culture vaccines may offer safer poultry options; leaves open prospective trials before any practice shift.
Hydropericardium syndrome (HPS) is a fatal disease of broiler chickens causing high mortality and heavy economic losses in various countries. More than 100 million birds have been affected by this destructive disease in less than two years worldwide. As it is a viral disease, the only solution is to vaccinate chickens. Different types of vaccines are being used against this disease in different areas of the world. Liver organ inactivated vaccines are more extensively used to control the disease initially. These vaccines have many drawbacks regarding their dose, un-predictable immune response and secondary bacterial infections. Following this, oil adjuvant vaccine was used to control the disease, however the handling stress and the formation of granuloma at the site of injection remains a problem. Consequently there is a need for cell culture adapted and attenuated vaccines, which can be administered through oral routes. A chicken embryo-adapted inactivated vaccine has shown good results but requires a continuous supply of specific, pathogen-free chicken embryos and a continuous life killing process. The continuous cell lines are a more promising solution for the production of cell culture-adapted and attenuated vaccines, which are safer, more economical and easy to administer. The following review discusses the development of modern HPS vaccines.
No takes yet. Share an insight, caveat, or question.
Mahmood et al. (2014) conducted a review in Hydropericardium syndrome (HPS). Hydropericardium syndrome vaccines was evaluated. The review discusses the development of modern hydropericardium syndrome vaccines, highlighting the need for cell culture-adapted and attenuated vaccines over traditional liver organ inactivated vaccines.
Synapse has enriched 10 related papers. Consider them for comparative context: